Abstract
Metabolic modulation during myocardial ischemia is possible by the use of specific drugs, which may induce a shift from free fatty acid towards predominantly glucose utilization by the myocardium to increase ATP generation per unit oxygen consumption. Three agents (trimetazidine, ranolazine, and perhexiline) have well-documented anti-ischaemic effects. However, perhexiline, the most potent agent currently available, requires plasma-level monitoring to avoid hepatoneuro- toxicity. Besides, the long-term safety of trimetazidine and ranolazine has yet to be established. In addition to their effect in ischemia, the potential use of these drugs in chronic heart failure is gaining recognition as clinical and experimental data are showing the improvement of myocardial function following treatment with several of them, even in the absence of ischemia. Future applications for this line of treatment is promising and deserves additional research. In particular, large, randomised, controlled trials investigating the effects of these agents on mortality and hospitalization rates due to coronary artery disease are needed.
Keywords: Metabolic modulation, cardiac ischemia, myocardial infarct, reperfusion, ischemic preconditioning
Current Pharmaceutical Design
Title: Modulation of Cardiac Metabolism During Myocardial Ischemia
Volume: 14 Issue: 25
Author(s): Antonio C.P. Chagas, Paulo M.M. Dourado and Tatiana de Fatima Goncalves Galvao
Affiliation:
Keywords: Metabolic modulation, cardiac ischemia, myocardial infarct, reperfusion, ischemic preconditioning
Abstract: Metabolic modulation during myocardial ischemia is possible by the use of specific drugs, which may induce a shift from free fatty acid towards predominantly glucose utilization by the myocardium to increase ATP generation per unit oxygen consumption. Three agents (trimetazidine, ranolazine, and perhexiline) have well-documented anti-ischaemic effects. However, perhexiline, the most potent agent currently available, requires plasma-level monitoring to avoid hepatoneuro- toxicity. Besides, the long-term safety of trimetazidine and ranolazine has yet to be established. In addition to their effect in ischemia, the potential use of these drugs in chronic heart failure is gaining recognition as clinical and experimental data are showing the improvement of myocardial function following treatment with several of them, even in the absence of ischemia. Future applications for this line of treatment is promising and deserves additional research. In particular, large, randomised, controlled trials investigating the effects of these agents on mortality and hospitalization rates due to coronary artery disease are needed.
Export Options
About this article
Cite this article as:
Chagas C.P. Antonio, Dourado M.M. Paulo and Goncalves Galvao de Fatima Tatiana, Modulation of Cardiac Metabolism During Myocardial Ischemia, Current Pharmaceutical Design 2008; 14 (25) . https://dx.doi.org/10.2174/138161208786071236
DOI https://dx.doi.org/10.2174/138161208786071236 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Health Promoting Effect of Dietary Polyphenols
Current Nutrition & Food Science Phytochemicals as Prototypes for Pharmaceutical Leads Towards Drug Development Against Diabetic Cardiomyopathy
Current Pharmaceutical Design The Pleiotropic Effects of ARB in Vascular Endothelial Progenitor Cells
Current Vascular Pharmacology Endogenous and Exogenous Ligands of Aryl Hydrocarbon Receptor: Current State of Art
Current Drug Metabolism Clinical Uses of Heliox Mixtures in Chronic Obstructive Pulmonary Disease
Current Respiratory Medicine Reviews Beta-Blockers in Children with Congenital Heart Disease Before a Corrective Procedure
Reviews on Recent Clinical Trials Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging
Current Medical Imaging Regulation of Angiogenesis by Macrophages, Dendritic Cells, and Circulating Myelomonocytic Cells
Current Pharmaceutical Design Alternative Gene Therapy Strategies for the Repair of Craniofacial Bone Defects
Current Gene Therapy Contemporary Management of Hypertension - How to Optimize Therapy
Cardiovascular & Hematological Disorders-Drug Targets Biochemical Strategies to Anticoagulation: A Comparative Overview
Current Vascular Pharmacology Takotsubo Syndrome: Clinical Manifestations, Etiology and Pathogenesis
Current Cardiology Reviews F508del-CFTR Rescue: A Matter of Cell Stress Response
Current Pharmaceutical Design Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Current Drug Targets Peptidyl Fluoro-Ketones as Proteolytic Enzyme Inhibitors
Current Topics in Medicinal Chemistry The Cellular and Molecular Basis of Health Benefits of Grape Seed Proanthocyanidin Extract
Current Pharmaceutical Biotechnology Cardiac Stem Cell Characteristics in Physiological and Pathological Conditions
Current Pharmaceutical Design Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Advances in the Physiology of GPR55 in the Central Nervous System
Current Neuropharmacology Pathophysiological Roles of Nitric Oxide: In the Heart and the Coronary Vasculature
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents